In today's world, Tipranavir has become a topic of great relevance and interest to a large number of people. Whether due to its impact on society, its historical relevance or its influence on various aspects of daily life, Tipranavir has captured the attention of a wide audience. From its origins to its current evolution, Tipranavir continues to generate debates, reflections and deep analysis. In this article, we will explore different aspects related to Tipranavir, with the aim of delving into its importance and better understanding its impact on the modern world.
Clinical data | |
---|---|
Pronunciation | /tɪpˈrænəvɪər/ tip-RAN-ə-veer |
Trade names | Aptivus |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606009 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth (soft capsules) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99.9% |
Metabolism | Liver |
Elimination half-life | 4.8–6 hours |
Excretion | Feces (82.3%), urine (4.4%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.066 |
Chemical and physical data | |
Formula | C31H33F3N2O5S |
Molar mass | 602.67 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tipranavir (TPV), or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer Ingelheim under the trade name Aptivus /ˈæptɪvəs/ AP-tiv-əs. It is administered with ritonavir in combination therapy to treat HIV infection.[citation needed]
Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and is recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations. Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.
Tipranavir should only be taken in combination with ritonavir and other antiretroviral drugs, and is not approved for treatment-naïve patients. Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with drug resistance. However, side effects of tipranavir may be more severe than those of other antiretrovirals. Some side effects include intracranial hemorrhage, hepatitis, hepatic decompensation, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.
Aptivus labeling has a black box warning regarding hepatotoxicity and intracranial hemorrhage.